Avrobio Company
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Technology:
Atrificial Vectors and Immune Cells, Cell-based gene therapy
Industry:
Atrificial Vectors and Immune Cells, Public
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2015-01-01
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
10
Total Funding:
85000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2018-02-01
Last Funding Type:
Series B
Register and Claim Ownership